Gilead announces Novo Nordisk NASH partnership after new data revealed
The companies will collaborate for a clinical trial combining compounds from their respective pipelines in NASH.
Read More
Tag: nonalcoholic steatohepatitis
Tiziana submits IND for Foralumab oral formulation in NASH
Tiziana has submitted an Investigational New Drug application for an oral formulation of Foralumab.
Read More
Intercept’s fatty liver drug one step closer to approval
Intercept Pharmaceuticals has announced that its treatment in patients with a progressive fatty liver disease showed an improvement in scarring on the organ.
Read More
AZ buys Ionis’ NASH candidate
AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
